Veradigm (MDRX, Financial) is making strides in the field of artificial intelligence by enhancing the production of real-world evidence for GLP-1 receptor agonists, which include semaglutide and tirzepatide. The company is utilizing AI to analyze deidentified data from electronic health records within its network. This advancement allows researchers to uncover comprehensive insights such as potential side effects, reasons for discontinuation, and social health determinants, which previously required labor-intensive manual data processing.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Veradigm Inc (MDRX, Financial) is $14.33 with a high estimate of $26.00 and a low estimate of $10.00. The average target implies an upside of 233.33% from the current price of $4.30. More detailed estimate data can be found on the Veradigm Inc (MDRX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Veradigm Inc's (MDRX, Financial) average brokerage recommendation is currently 2.6, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
